Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
暂无分享,去创建一个
M. Moasser | H. Rugo | A. Goga | John W. Park | P. Munster | A. Chien | M. Melisko | K. Koch | K. Ordovas | E. Khanafshar | G. Auerback
[1] Andrew Z. Wang. Giving failed drugs a fresh chance: a new direction for nanoparticle drug delivery , 2012, Expert review of medical devices.
[2] Eric T. Kim,et al. Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization , 2012, Cell.
[3] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[4] Kostas Kostarelos,et al. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. , 2011, Accounts of chemical research.
[5] William Pao,et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.
[6] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[7] Yan Sun,et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Mueller. Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility. , 2010 .
[9] J. Baselga,et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Dhara N. Amin,et al. Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver , 2010, Science Translational Medicine.
[11] Saeed Sadeghi,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Jin Sun,et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. , 2009, Recent patents on anti-cancer drug discovery.
[13] T. Wakamatsu,et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies , 2009, British Journal of Cancer.
[14] Ronald A Fleming,et al. A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies , 2009, Clinical Cancer Research.
[15] Deborah A. Smith,et al. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. , 2009, British journal of clinical pharmacology.
[16] A. Stead,et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Sliwkowski,et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.
[18] S. Franco,et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[20] V. Stella,et al. Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.
[21] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[22] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[23] G. Bepler,et al. Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study , 2006, Clinical Cancer Research.
[24] P. Jänne,et al. Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2006, Clinical Cancer Research.
[25] M. Ellis,et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] ほか,et al. Imatinib Mesylate(STI 571)が著効した小腸Gastrointestinal Stromal Tumor術後腹腔内再発の1例 , 2005 .
[27] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[28] K. Koch,et al. Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. , 2004, Rapid communications in mass spectrometry : RCM.
[29] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[31] K. Lackey,et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.